DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

23.39B

Market cap23.39B

Price-Earnings ratio

25.92

Price-Earnings ratio25.92

Dividend yield

—

Dividend yield—

Average volume

5.77M

Average volume5.77M

High today

$61.37

High today$61.37

Low today

$60.12

Low today$60.12

Open price

$60.96

Open price$60.96

Volume

4.22M

Volume4.22M

52 Week high

$89.98

52 Week high$89.98

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

DexCom(DXCM) stock is priced at $60.50, giving the company a market capitalization of 23.39B. It carries a P/E multiple of 25.92.

On 2026-05-09, DexCom(DXCM) stock moved within a range of $60.12 to $61.37. With shares now at $60.50, the stock is trading +0.6% above its intraday low and -1.4% below the session's peak.

Trading volume for DexCom(DXCM) stock has reached 4.22M, versus its average volume of 5.77M.

The stock's 52-week range extends from a low of $54.11 to a high of $89.98.

DXCM News

TipRanks 19h

Dexcom: Buy Rating Reiterated with Attractive Growth Outlook and Unchanged $80 Price Target

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Dexcom. The associated price target remains the same with $80.00. Unlock hedge fund-level da...

Simply Wall St 2d

How Investors May Respond To DexCom Strong Q1 2026 Earnings And Reaffirmed Revenue Outlook

DexCom, Inc. reported past first-quarter 2026 results with sales of US$1.19 billion and net income of US$199.5 million, alongside higher basic and diluted EPS f...

TipRanks 5d

DexCom price target lowered to $79 from $84 at Citi

Citi analyst Joanne Wuensch lowered the firm’s price target on DexCom (DXCM) to $79 from $84 and keeps a Buy rating on the shares. Unlock hedge fund-level data...

Analyst ratings

84%

of 31 ratings

Buy

83.9%

Hold

12.9%

Sell

3.2%

More DXCM News

Simply Wall St 6d

Assessing DexCom Valuation After Strong Q1 Results And Expanded CGM Coverage

DexCom (DXCM) is back in focus after first quarter 2026 earnings, reporting revenue of US$1.19b and net income of US$199.5m, alongside reaffirmed full year reve...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.